BACKGROUND
Abolis fuses recent advances in biology, bioinformatics, genetics and robotics to reprogram microorganisms for the production of molecules or proteins of interest. By modifying the metabolic pathways of life, the company’s technology creates industrial microbial strains capable of producing molecules of interest via fermentation.
The core concept guiding Abolis is to seek inspiration in and improve upon what nature has been doing for eons: biosynthesis.
DESCRIPTION OF THE PRODUCTS / SERVICES /TECHNOLOGY
With its synthetic biology platform, Abolis reliably provides businesses with the existing or novel molecules they need while maintaining sustainability (bio-based and/or biodegradable materials) and significantly reducing the environmental impact of molecular production.
Abolis accompanies its clients from the project study phase, through the securing of intellectual property and on to industrialization start-up
ACCOMPLISHMENTS / COLLABORATIONS / HIGHLIGHTS
Abolis works with a number of major groups in the cosmetics, pharmaceuticals and nutrition sectors.
The company was selected within the France Relance 2021 project.
As of year-end 2021, Abolis employs more than 40 people.
The first applications resulting from Abolis’ technology will reach the market in 2024.
Collaborations sought
Abolis pursues its own research program.
In parallel, the company establishes industrial partnerships to:
- biosource the production of its clients’ molecules;
- secure the supply of raw materials for them by relocalizing production;
- and furnish them with rare and/or complex compounds.
